IBM Research to collaborate with Melanoma Institute Australia

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

IBM Research will undertake research with Melanoma Institute Australia to help further advance the identification of melanoma using cognitive technology.

This research builds on IBM’s existing research agreement with MoleMap, which uses advanced visual analytics to analyze more than 40,000 data sets including images and text. IBM Research plans to analyze dermatological images of skin lesions to help identify specific clinical patterns in the early stages of melanoma. The Australian research team aims to help reduce unnecessary biopsies and help clinicians more accurately understand skin cancer, which could help to improve patient care.

YOU MAY BE INTERESTED IN

In April 2025, announcements from the two most influential biomedical agencies in the US, the FDA and the NIH, declared that both will seek to reduce and minimize animal-based testing and experimentation. These declarations sparked joy in some circles, and deep concern in others that was reflected in a 28% fall in the share price of Charles River Labs (NYSE: NYSE:CRL). 
Over the past three decades, cancer genetics has transformed precision oncology. Germline testing has advanced from single-gene Sanger sequencing to parallel sequencing of hundreds of genes, while tumor (somatic) testing has expanded with the rise of targeted therapies based on point mutations, copy number changes and other alterations. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login